Pharmacogenomics of Drug Metabolizing Enzymes and Transporters:Relevance to Precision Medicine

被引:0
|
作者
Shabbir Ahmed [1 ]
Zhan Zhou [1 ]
Jie Zhou [1 ]
Shu-Qing Chen [1 ,2 ]
机构
[1] Department of Precision Medicine and Biopharmaceutics,College of Pharmaceutical Sciences,Zhejiang University
[2] International Center for Precision Medicine,Zhejiang California International Nano Systems Institute
基金
中国国家自然科学基金;
关键词
Pharmacogenomics; Precision medicine; Genetic polymorphism; Phase-I drug-metabolizing enzymes; Drug transporters;
D O I
暂无
中图分类号
R96 [药理学];
学科分类号
100602 ; 100706 ;
摘要
The interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enables the evaluation of some specific genetic variants responsible for an individual’s particular drug response. In this article, we review the contributions of genetic polymorphisms to major individual variations in drug pharmacotherapy, focusing specifically on the pharmacogenomics of phase-I drug metabolizing enzymes and transporters. Substantial frequency differences in key variants of drug metabolizing enzymes and transporters, as well as their possible functional consequences, have also been discussed across geographic regions. The current effort illustrates the common presence of variability in drug responses among individuals and across all geographic regions. This information will aid health-care professionals in prescribing the most appropriate treatment aimed at achieving the best possible beneficial outcomes while avoiding unwanted effects for a particular patient.
引用
收藏
页码:298 / 313
页数:16
相关论文
共 50 条
  • [21] Pharmacogenomics to achieve precision medicine
    Empey, Philip E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (23) : 1906 - 1907
  • [22] Contribution of -omics methodologies to veterinary pharmacology and toxicology, with special emphasis on drug metabolizing enzymes and drug transporters
    Dacasto, M.
    Giantin, M.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2018, 41 : 82 - 83
  • [23] Hepatic drug-metabolizing enzymes and drug transporters in Wilson’s disease patients with liver failure
    Sylwia Szeląg-Pieniek
    Stefan Oswald
    Mariola Post
    Joanna Łapczuk-Romańska
    Marek Droździk
    Mateusz Kurzawski
    Pharmacological Reports, 2021, 73 : 1427 - 1438
  • [24] Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes
    Wegler, Christine
    Gaugaz, Fabienne Z.
    Andersson, Tommy B.
    Wisniewsk, Jacek R.
    Busch, Diana
    Groeer, Christian
    Oswald, Stefan
    Noren, Agneta
    Weiss, Frederik
    Hammer, Helen S.
    Joos, Thomas O.
    Poetz, Oliver
    Achour, Brahim
    Rostami-Hodjegan, Amin
    van de Steeg, Evita
    Wortelboer, Heleen M.
    Artursson, Per
    MOLECULAR PHARMACEUTICS, 2017, 14 (09) : 3142 - 3151
  • [25] Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective
    Umamaheswaran, Gurusamy
    Kumar, Dhakchinamoorthi Krishna
    Adithan, Chandrasekaran
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2014, 139 : 27 - 65
  • [26] An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: Experience in Singapore
    Chowbay, B
    Zhou, SF
    Lee, EJD
    DRUG METABOLISM REVIEWS, 2005, 37 (02) : 327 - 378
  • [27] Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine
    Biswas, Mohitosh
    Shobana, John
    Jinda, Pimonpan
    Sukasem, Chonlaphat
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (03) : 165 - 174
  • [28] Hepatic drug-metabolizing enzymes and drug transporters in Wilson's disease patients with liver failure
    Szelag-Pieniek, Sylwia
    Oswald, Stefan
    Post, Mariola
    Lapczuk-Romanska, Joanna
    Drozdzik, Marek
    Kurzawski, Mateusz
    PHARMACOLOGICAL REPORTS, 2021, 73 (05) : 1427 - 1438
  • [29] Pharmacogenomics/updated for precision medicine in dermatology
    Le Hanh Dung Do
    Maibach, Howard
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (04) : 410 - 413
  • [30] Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
    Bleasby, Kelly
    Houle, Robert
    Hafey, Michael
    Lin, Meihong
    Guo, Jingjing
    Lu, Bing
    Sanchez, Rosa I.
    Fillgrove, Kerry L.
    VIRUSES-BASEL, 2021, 13 (08):